The Efficacy of Paclitaxel and Cisplatin Combination Chemotherapy for the Treatment of Metastatic or Recurrent Gastric Cancer: a Multicenter Phase II Study.
10.3904/kjim.2005.20.2.135
- Author:
Sang Joon SHIN
1
;
Sung Ho CHUN
;
Kyeong Ok KIM
;
Min Kyoung KIM
;
Kyung Hee LEE
;
Myung Soo HYUN
;
Sung Hwa BAE
;
Hun Mo RYOO
;
Young Rok DO
;
Ki Young KWON
;
Hong Suk SONG
Author Information
1. Division of Oncology-Hematology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. hms@med.yu.ac.kr
- Publication Type:Original Article ; Clinical Trial ; Clinical Trial, Phase II ; Multicenter Study
- Keywords:
Stomach Neoplasms;
Paclitaxel
- MeSH:
Adult;
Aged;
Antineoplastic Agents/*therapeutic use;
Antineoplastic Agents, Phytogenic/therapeutic use;
Cisplatin/*therapeutic use;
Drug Therapy, Combination;
Female;
Follow-Up Studies;
Humans;
Male;
Middle Aged;
Neoplasm Metastasis/drug therapy;
Neoplasm Recurrence, Local/*drug therapy;
Paclitaxel/*therapeutic use;
Prospective Studies;
Safety;
Stomach Neoplasms/*drug therapy/*secondary;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2005;20(2):135-140
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Although many treatments for advanced gastric cancer have been developed, only poor treatment results have generally been obtained. We performed a prospective study on the combination chemotherapy of paclitaxel and cisplatin (PC). The primary objectives of the study were elucidating the disease response and evaluating the drug regimen's safety. METHODS: Patients with metastatic or recurrent gastric cancer received intravenous paclitaxel 175 mg/m2, and cisplatin 70 mg/m2 on day 1. This cycle was repeated every 3 weeks. RESULTS: From January 2000 to March 2004, 37 patients from 3 different hospitals were enrolled in this study. A total of 135 treatment cycles (median: 3 cycles) were administered. The responses were evaluable in 34 patients; 24 patients received this regimen as their first-line treatment for metastatic cancer and the other patients received it as their second-line treatment for recurrent cancer. The objective response rate (RR) was 26.5% (95% CI: 11.7-41.3) with two complete responses, and stable disease was observed in 41.1% of the patients. Importantly, an RR of 33.3% (95% CI: 0.6-66.0) was achieved for the eight patients who received this regimen as a first-line treatment. The median follow up duration was 14 months for all the patients, and the median time to progression was 6 months (95% CI: 1.9-10.2). The overall survival time was 8.9 months (95% CI: 7.0-11.0) with a 1-year survival rate of 18.7% (95% CI: 5.6-31.8). The most common toxicity was neutropenia. CONCLUSION: PC exhibited promising activity against gastric cancer for the previously untreated patients as a first-line treatment with an acceptable toxicity profile.
